MediGene releases preliminary Phase II data of EndoTAG-1 in breast cancer
This article was originally published in Scrip
Executive Summary
MediGene has released preliminary data from a Phase II trial of its lead drug candidate EndoTAG-1 (cationic lipid complexed paclitaxel) in triple-negative breast cancer (TNBC), which it hopes will help bring a partner to the table to develop the therapy in Phase III.